KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Operations (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash from Operations for 15 consecutive years, with 19861000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 55.27% to 19861000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 47331000.0, a 72.47% decrease, with the full-year FY2025 number at 47331000.0, down 72.47% from a year prior.
  • Cash from Operations was 19861000.0 for Q4 2025 at Supernus Pharmaceuticals, up from 61664000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 71119000.0 in Q2 2022 to a low of 61664000.0 in Q3 2025.
  • A 5-year average of 28716000.0 and a median of 36037500.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 1041.93% in 2023, then crashed 215.22% in 2025.
  • Supernus Pharmaceuticals' Cash from Operations stood at 48763000.0 in 2021, then tumbled by 43.47% to 27564000.0 in 2022, then surged by 63.1% to 44958000.0 in 2023, then dropped by 1.23% to 44406000.0 in 2024, then tumbled by 55.27% to 19861000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash from Operations are 19861000.0 (Q4 2025), 61664000.0 (Q3 2025), and 58535000.0 (Q2 2025).